Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Metformin for Cardioprotection in Breast Cancer Patients on Doxorubicin
NCT07815808Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin, liquid metformin (Aspargo Labs) in Cardiotoxicity, sponsored by Tanta University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07815808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815808.